Hodgkin Lymphoma
Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 9, 2023
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Listen Now
Cecilia BrownHodgkin Lymphoma | January 5, 2023
Post-AHSCT consolidation with brentuximab vedotin plus nivolumab was “highly active” in relapsed/refractory Hodgkin ...
Kerri FitzgeraldHodgkin Lymphoma | December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Leah SherwoodHodgkin Lymphoma | November 21, 2022
The FDA approved brentuximab vedotin for pediatric patients with previously untreated high-risk classic Hodgkin lymphoma.
Leah SherwoodHodgkin Lymphoma | November 15, 2022
Penpulimab demonstrated a good safety profile in patients with relapsed/refractory classical Hodgkin lymphoma.
Leah LawrenceHodgkin Lymphoma | May 10, 2022
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
Leah LawrenceHodgkin Lymphoma | April 15, 2022
The allogeneic dual CAR T-cell product demonstrated preclinical activity for patients with relapsed or refractory non-Hodgkin ...
Leah LawrenceHodgkin Lymphoma | April 11, 2022
NK Cells Complexed with Bispecific Antibody Active in Advanced Lymphoma
Leah LawrenceHodgkin Lymphoma | April 4, 2022
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion ...
Sabrina AhleHodgkin Lymphoma | March 12, 2022
Oxford Biodynamics has announced the US launch of its clinical blood test predicting the likelihood of response to immune ...
Sabrina AhleHodgkin Lymphoma | March 2, 2022
Researchers examined survival rates by age in patients with Hodgkin lymphoma receiving response-adapted therapy on ...
Sabrina AhleHodgkin Lymphoma | February 25, 2022
The FDA has issued draft guidance on clinical pharmacology considerations for potential manufacturers of antibody drug ...
Sabrina AhleMantle Cell Lymphoma | February 8, 2022
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Kami Maddocks, MDAggressive B-Cell Lymphoma | January 20, 2022
Dr. Maddocks reflects on her small-town upbringing and learning to love triathlons.
Rebecca AraujoMantle Cell Lymphoma | November 15, 2021
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Rebecca AraujoHodgkin Lymphoma | November 12, 2021
Older patients are at a significantly increased risk of immune-related AEs.
Rebecca AraujoAcute Lymphoblastic Leukemia | October 11, 2021
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Editorial Board